< -5%

-5% to -3%

-3% to 0%

Photoquip India

Jindal Photo

SGL Resources

0% to 3%

CHOKSI ASIA

3% to 5%

Bajaj Finance on December 2 announced that it has sold around 2 percent stake in its subsidiary Bajaj Housing Finance for a total consideration of approximately Rs 1,588 crore.

The company made the announcement in the post markets hours of Tuesday.
<h3><strong>Bajaj Finance sells 2% stake in Bajaj Housing Finance:</strong></h3>
<a href="https://www.moneycontrol.com/india/stockpricequote/finance-nbfc/bajajfinance/BAF">Bajaj Finance</a> said that the company sold 16.66 crore shares in its subsidiary in the open market via a bulk deal at at Rs 95.3074 per share. "The sale was carried out as a step towards achieving the Minimum Public Shareholding requirements in BHFL," the firm said.

As at the end of the July-September quarter of the ongoing financial year 2026, Bajaj Finance held 88.70 percent stake in Bajaj Housing Finance, while the rest was held by the general public, according to data on the company's shareholding pattern.

After the <a href="https://www.moneycontrol.com/news/business/markets/block-deal-impact-bajaj-housing-finance-shares-fall-9-to-52-week-low-amid-buzz-of-promoter-s-2-stake-sale-13705806.html">stake sale</a>, Bajaj Finance holds 86.70 percent stake in Bajaj Housing Finance.
<h3><strong>Bajaj Housing Finance shares tumble after bulk deal:</strong></h3>
The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/finance-housing/bajajhousingfinance/BHFL">Bajaj Housing Finance</a> tumbled more than 9 percent on December 2 to hit an intraday low of Rs 95 apiece. This was the lowest level seen by the stock so far since bumper debut in September 2024. The stock then recovered some losses to close more than 7 percent lower at Rs 97.15 apiece.

Bajaj Housing Finance had made a bumper market debut in September last year, listing with a premium of 114 percent over the IPO issue price at Rs 150 per share. The Rs 6,560-crore initial public offer (IPO) saw strong investor interest during its three days of public bidding, being subscribed more than 67 times its offer size.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Ownership, Material Conflicts of Interest and Disciplinary History

MCD is a wholly owned subsidiary of Network 18 Media & Investments Ltd ("Network18"), in which Independent Media Trust (IMT) holds 56.89% stake. Reliance Industries Limited ("RIL") is the sole beneficiary of IMT. Network18 and RIL and their subsidiaries, joint ventures and associates can be considered as associates of MCD.

Details of Associate

Receipt of Compensation

Third-Party Compensation

Employment History

Market-Making Activities

Use of Artificial Intelligence

Bajaj Finance raises Rs 1,588 crore by selling nearly 2% stake in Bajaj Housing Finance

Bajaj Finance on December 2 announced that it has sold around 2 percent stake in its subsidiary Bajaj Housing Finance for a total consideration of approximately Rs 1,588 crore.

The company made the announcement in the post markets hours of Tuesday.
Bajaj Finance sells 2% stake in Bajaj Housing Finance:
Bajaj Finance said that the company sold 16.66 crore shares in its subsidiary in the open market via a bulk deal at at Rs 95.3074 per share. &quot;The sale was carried out as a step towards achieving the Minimum Public Shareholding requirements in BHFL,&quot; the firm said.

As at the end of the July-September quarter of the ongoing financial year 2026, Bajaj Finance held 88.70 percent stake in Bajaj Housing Finance, while the rest was held by the general public, according to data on the company's shareholding pattern.

After the stake sale, Bajaj Finance holds 86.70 percent stake in Bajaj Housing Finance.
Bajaj Housing Finance shares tumble after bulk deal:
The shares of Bajaj Housing Finance tumbled more than 9 percent on December 2 to hit an intraday low of Rs 95 apiece. This was the lowest level seen by the stock so far since bumper debut in September 2024. The stock then recovered some losses to close more than 7 percent lower at Rs 97.15 apiece.

Bajaj Housing Finance had made a bumper market debut in September last year, listing with a premium of 114 percent over the IPO issue price at Rs 150 per share. The Rs 6,560-crore initial public offer (IPO) saw strong investor interest during its three days of public bidding, being subscribed more than 67 times its offer size.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/paintsvarnishes/asianpaints/AP31">Asian Paints</a> jumped more than 3 percent to emerge as the top Nifty 50 gainer on December 2. This comes as positive brokerage call by UBS lifted investor sentiment.

The shares of the paint-maker hit a fresh 52-week high of Rs 2,959.90 apiece in the afternoon. The stock later pared some minor gains to close at Rs 2,958 apiece.
<h3><strong>UBS upgrades Asian Paints rating:</strong></h3>
UBS upgraded the rating of Asian Paints to 'Neutral' from 'Sell', and raised its target price to Rs 3,200 per share from Rs 2,100 per share. The latest target price implies an upside potential of nearly 12 percent from the stock’s previous closing price of Rs 2,867.6 per share.

The international brokerage noted that Asian Paints delivered a double-digit volume growth and better-than-expected results in the second quarter of FY26, despite weak demand environment. It added that the company had highlighted that it intends to maintain volume momentum in the second half of the ongoing FY26.

UBS sees the volume outlook for second half of FY26 to be positive, and expects market conditions to improve in near term.
<h3><strong>Asian Paints Q2 Results:</strong></h3>
Asian Paints on November 12 reported a net profit of Rs 993.59 crore for Q2 FY26. This marks a 43 percent YoY rise from the Rs 694.64 crore net profit reported in Q2 FY25. The firm's revenue from operations meanwhile rose 6 percent YoY to Rs 8,513.70 crore.
<h3><strong>Asian Paints share price history:</strong></h3>
Asian Paints shares have jumped around 18 percent in the past one month, and over 30 percent in the past six months. The stock is up more than 28 percent in 2025 so far.

Its P/E ratio currently stands at around 79.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-sensex-nifty-50-share-price-gift-nifty-latest-updates-02-12-2025-liveblog-13705444.html">LIVE updates</a> from the stock markets here.

<em>(With inputs from Reuters)</em>

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Asian Paints shares jump 3%, hit new 52-week high after UBS upgrades stock to 'Neutral': Check latest target price

The shares of Asian Paints jumped more than 3 percent to emerge as the top Nifty 50 gainer on December 2. This comes as positive brokerage call by UBS lifted investor sentiment.

The shares of the paint-maker hit a fresh 52-week high of Rs 2,959.90 apiece in the afternoon. The stock later pared some minor gains to close at Rs 2,958 apiece.
UBS upgrades Asian Paints rating:
UBS upgraded the rating of Asian Paints to 'Neutral' from 'Sell', and raised its target price to Rs 3,200 per share from Rs 2,100 per share. The latest target price implies an upside potential of nearly 12 percent from the stock’s previous closing price of Rs 2,867.6 per share.

The international brokerage noted that Asian Paints delivered a double-digit volume growth and better-than-expected results in the second quarter of FY26, despite weak demand environment. It added that the company had highlighted that it intends to maintain volume momentum in the second half of the ongoing FY26.

UBS sees the volume outlook for second half of FY26 to be positive, and expects market conditions to improve in near term.
Asian Paints Q2 Results:
Asian Paints on November 12 reported a net profit of Rs 993.59 crore for Q2 FY26. This marks a 43 percent YoY rise from the Rs 694.64 crore net profit reported in Q2 FY25. The firm's revenue from operations meanwhile rose 6 percent YoY to Rs 8,513.70 crore.
Asian Paints share price history:
Asian Paints shares have jumped around 18 percent in the past one month, and over 30 percent in the past six months. The stock is up more than 28 percent in 2025 so far.

Its P/E ratio currently stands at around 79.

Follow all LIVE updates from the stock markets here.

(With inputs from Reuters)

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

The shares of Sun Pharma Advanced Research Company (<a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/sunpharmaadvancedresearchcompany/SPA">SPARC</a>) jumped 20 percent on December 2. This comes after a US district court passed an order in favour of the company for its 'Sezaby' injection.

The shares of the pharma company hit the upper circuit at Rs 161.02 apiece, the highest level seen by the stock since end of July this year.
<h3><strong>Here's what triggered SPARC's share price rally:</strong></h3>
In an exchange filing, SPARC announced that the US District Court for the District of Columbia has granted summary judgement in favour of the company in regard with the issuance of Priority Review Voucher (PRV) associated with the approval of Sezaby.

The court granted SPARC’s motion for summary judgment and held that "FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved' as that term is used in the statute". It has allowed 60 days to appeal against the motion.

Speaking about the development, SPARC CEO Anil Raghavan said, "We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARC’s long held position on this matter."

Sezaby is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures.
<h3><strong>SPARC share price:</strong></h3>
The sharp rise in the share price comes on the back of strong trading volumes. Nearly 2.6 crore shares have changed hands in trade so far. This is around 117 times that of the stock’s 10-day average volumes.

The shares are currently trading higher than its 200-day average. Despite today's sharp gains, SPARC shares have fallen nearly 19 percent in the past six months, and are down nearly 20 percent in 2025 so far.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-sensex-nifty-50-share-price-gift-nifty-latest-updates-02-12-2025-liveblog-13705444.html">LIVE updates</a> from the stock markets here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

SPARC shares soar 20% after US district court passes favourable judgement for Sezaby PRV

The shares of Sun Pharma Advanced Research Company (SPARC) jumped 20 percent on December 2. This comes after a US district court passed an order in favour of the company for its 'Sezaby' injection.

The shares of the pharma company hit the upper circuit at Rs 161.02 apiece, the highest level seen by the stock since end of July this year.
Here's what triggered SPARC's share price rally:
In an exchange filing, SPARC announced that the US District Court for the District of Columbia has granted summary judgement in favour of the company in regard with the issuance of Priority Review Voucher (PRV) associated with the approval of Sezaby.

The court granted SPARC’s motion for summary judgment and held that &quot;FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved' as that term is used in the statute&quot;. It has allowed 60 days to appeal against the motion.

Speaking about the development, SPARC CEO Anil Raghavan said, &quot;We are pleased with the ruling issued today by the U.S. District Court, as it validates SPARC’s long held position on this matter.&quot;

Sezaby is a benzyl alcohol and propylene glycol free formulation of phenobarbital sodium powder for injection. It was approved by the US FDA for the treatment of neonatal seizures.
SPARC share price:
The sharp rise in the share price comes on the back of strong trading volumes. Nearly 2.6 crore shares have changed hands in trade so far. This is around 117 times that of the stock’s 10-day average volumes.

The shares are currently trading higher than its 200-day average. Despite today's sharp gains, SPARC shares have fallen nearly 19 percent in the past six months, and are down nearly 20 percent in 2025 so far.

Follow all LIVE updates from the stock markets here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

The shares of Delhivery dropped in trade on December 2 after Jefferies said the increasing reliance of soon-to-be-listed Meesho on its in-house low logistics arm Valmo acts as a key downside risk for the logistics platform.

<a href="https://www.moneycontrol.com/india/stockpricequote/courier-services/delhivery/D06">Delhivery</a> shares fell more than 1 percent to trade at Rs 412.90 apiece in the morning of Tuesday.
<h3><strong>Here's what Jefferies said:</strong></h3>
Jefferies in its latest note maintained an 'Underperform' rating on the stock, with a target price of Rs 390 per share. This implies a downside potential of nearly 7 percent from the stock’s previous closing price of Rs 417.6 apiece.

According to Meesho's draft IPO papers filed with SEBI, the company shipped nearly 29.6 crore orders through Valmo during the April-June quarter of the ongoing financial year, as against 18 crore orders shipped through end-to-end express parcel delivery companies like Delhivery. This is sharply different from the trend seen in earlier years, where majority of the orders were shipped through the third-party delivery companies.

Jefferies noted that Valmo now handles approximately 50 percent of Meesho's shipments at a lower cost, as against third party logistics providers such as Delhivery.

The international brokerage estimated that Meesho accounted for roughly 16 percent of Delhivery's FY25 revenue. Hence, Meesho’s shift to insourcing could weigh on Delhivery's mainstay express parcels growth, it added.
<h3><strong>Meesho IPO:</strong></h3>
SoftBank-backed e-commerce platform <a href="https://www.moneycontrol.com/ipo/meesho-ltd-ml13-ipodetail">Meesho</a> will launch its much-awaited initial public offering (IPO) tomorrow, December 3. The company has fixed its price band at Rs 105-111 per share, valuing the business at nearly Rs 50,096 crore at the upper end.

The Rs 5,421.05-crore IPO comprises a fresh issue of shares worth Rs 4,250 crore and an offer for sale (OFS) of shares worth up to 10.55 crore shares by existing shareholders.
<h3><strong>Delhivery share price history:</strong></h3>
Delhivery shares have fallen nearly 12 percent in the past one month, but gained over 13 percent in the past six months. The stock is up more than 19 percent in 2025 so far.

The stock currently has a P/E ratio of around 158.

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-sensex-nifty-50-share-price-gift-nifty-latest-updates-02-12-2025-liveblog-13705444.html">LIVE updates</a> from the stock  markets here.

<em>(With inputs from Reuters)</em>

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

IPO-bound Meesho's increasing reliance on in-house low logistics arm could hurt Delhivery: Jefferies

The shares of Delhivery dropped in trade on December 2 after Jefferies said the increasing reliance of soon-to-be-listed Meesho on its in-house low logistics arm Valmo acts as a key downside risk for the logistics platform.

Delhivery shares fell more than 1 percent to trade at Rs 412.90 apiece in the morning of Tuesday.
Here's what Jefferies said:
Jefferies in its latest note maintained an 'Underperform' rating on the stock, with a target price of Rs 390 per share. This implies a downside potential of nearly 7 percent from the stock’s previous closing price of Rs 417.6 apiece.

According to Meesho's draft IPO papers filed with SEBI, the company shipped nearly 29.6 crore orders through Valmo during the April-June quarter of the ongoing financial year, as against 18 crore orders shipped through end-to-end express parcel delivery companies like Delhivery. This is sharply different from the trend seen in earlier years, where majority of the orders were shipped through the third-party delivery companies.

Jefferies noted that Valmo now handles approximately 50 percent of Meesho's shipments at a lower cost, as against third party logistics providers such as Delhivery.

The international brokerage estimated that Meesho accounted for roughly 16 percent of Delhivery's FY25 revenue. Hence, Meesho’s shift to insourcing could weigh on Delhivery's mainstay express parcels growth, it added.
Meesho IPO:
SoftBank-backed e-commerce platform Meesho will launch its much-awaited initial public offering (IPO) tomorrow, December 3. The company has fixed its price band at Rs 105-111 per share, valuing the business at nearly Rs 50,096 crore at the upper end.

The Rs 5,421.05-crore IPO comprises a fresh issue of shares worth Rs 4,250 crore and an offer for sale (OFS) of shares worth up to 10.55 crore shares by existing shareholders.
Delhivery share price history:
Delhivery shares have fallen nearly 12 percent in the past one month, but gained over 13 percent in the past six months. The stock is up more than 19 percent in 2025 so far.

The stock currently has a P/E ratio of around 158.

Follow all LIVE updates from the stock  markets here.

(With inputs from Reuters)

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

The shares of <a href="https://www.moneycontrol.com/india/stockpricequote/pharmaceuticals/wockhardt/W05">Wockhardt</a> extended sharp gains for the second consecutive session on December 2 after the company announced that the US FDA has formally accepted the New Drug Application (NDA) for its antibiotic Zaynich.

The stock jumped more than 6 percent to trade at Rs 1,566.90 apiece. The stock has now surged nearly 27 percent in just two days since the announcement. The market capitalization of the company has soared by Rs 5,400 crore in these two days of sharp gains to Rs 25,493 crore.
<h3><strong>US FDA accepts Wockhardt's NDA for antibiotic Zaynich:</strong></h3>
Zaynich targets complicated urinary tract infections (cUTIs) caused by multi-drug resistant (MDR) gram-negative bacteria.

Wockhardt in its exchange filing said that the NDA was first filed on September 30, and its acceptance marks a "transformative moment, not only for Wockhardt, but also for the entire Indian pharmaceutical industry". "This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA," it added.

The pharma company said that the United States Food and Drug Administration (US FDA) has granted fast track designation to Zaynich NDA, recognizing its potential to address urgent and unmet medical needs. "As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review," it added.

"A novel β-lactam enhancer mechanism based Zaynich has garnered international attention for its potent activity against highly resistant Gram-negative pathogens—microbes responsible for prolonged hospitalizations and significant mortality worldwide. Its life-saving impact has already been demonstrated through compassionate use in critically ill patients in both India and the United States," Wockhardt said.

The science-driven program to develop Zaynich was initiated by Wockhardt in 2011, and the pharma company said that it has successfully navigated a demanding non-clinical, clinical and regulatory pathway. "With Zaynich, Wockhardt continues to drive forward its mission of delivering path breaking anti-infective therapies that respond to some of the most serious threats in global healthcare," it added.

Speaking about the development, Wockhardt said, "The FDA's acceptance of the Zaynich NDA is a historic and proud moment for the organization and for India. It reaffirms our commitment to developing advanced anti-infective solutions for the world and demonstrates what Indian science and innovation can achieve on the global stage."

Follow all <a href="https://www.moneycontrol.com/news/business/markets/stock-market-live-sensex-nifty-50-share-price-gift-nifty-latest-updates-02-12-2025-liveblog-13705444.html">LIVE updates</a> from the stock markets here.

<em>Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.</em>

Wockhardt shares jump 6%, extend gain to 27% in two days after US FDA accepts new drug application for Zaynich

The shares of Wockhardt extended sharp gains for the second consecutive session on December 2 after the company announced that the US FDA has formally accepted the New Drug Application (NDA) for its antibiotic Zaynich.

The stock jumped more than 6 percent to trade at Rs 1,566.90 apiece. The stock has now surged nearly 27 percent in just two days since the announcement. The market capitalization of the company has soared by Rs 5,400 crore in these two days of sharp gains to Rs 25,493 crore.
US FDA accepts Wockhardt's NDA for antibiotic Zaynich:
Zaynich targets complicated urinary tract infections (cUTIs) caused by multi-drug resistant (MDR) gram-negative bacteria.

Wockhardt in its exchange filing said that the NDA was first filed on September 30, and its acceptance marks a &quot;transformative moment, not only for Wockhardt, but also for the entire Indian pharmaceutical industry&quot;. &quot;This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA,&quot; it added.

The pharma company said that the United States Food and Drug Administration (US FDA) has granted fast track designation to Zaynich NDA, recognizing its potential to address urgent and unmet medical needs. &quot;As part of this pathway, the FDA has committed to assign priority to Zaynich NDA review,&quot; it added.

&quot;A novel β-lactam enhancer mechanism based Zaynich has garnered international attention for its potent activity against highly resistant Gram-negative pathogens—microbes responsible for prolonged hospitalizations and significant mortality worldwide. Its life-saving impact has already been demonstrated through compassionate use in critically ill patients in both India and the United States,&quot; Wockhardt said.

The science-driven program to develop Zaynich was initiated by Wockhardt in 2011, and the pharma company said that it has successfully navigated a demanding non-clinical, clinical and regulatory pathway. &quot;With Zaynich, Wockhardt continues to drive forward its mission of delivering path breaking anti-infective therapies that respond to some of the most serious threats in global healthcare,&quot; it added.

Speaking about the development, Wockhardt said, &quot;The FDA's acceptance of the Zaynich NDA is a historic and proud moment for the organization and for India. It reaffirms our commitment to developing advanced anti-infective solutions for the world and demonstrates what Indian science and innovation can achieve on the global stage.&quot;

Follow all LIVE updates from the stock markets here.

Disclaimer: The views and investment tips expressed by experts on Moneycontrol are their own and not those of the website or its management. Moneycontrol advises users to check with certified experts before taking any investment decisions.

Photographic Products Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Photographic Products industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Bajaj Finance raises Rs 1,588 crore by selling nearly 2% stake in Bajaj Housing Finance

Asian Paints shares jump 3%, hit new 52-week high after UBS upgrades stock to 'Neutral': Check latest target price

SPARC shares soar 20% after US district court passes favourable judgement for Sezaby PRV

IPO-bound Meesho's increasing reliance on in-house low logistics arm could hurt Delhivery: Jefferies

Wockhardt shares jump 6%, extend gain to 27% in two days after US FDA accepts new drug application for Zaynich

Photographic Products Industry StocksCheck latest stock performance, list of stocks, earnings review & more details about the Photographic Products industry stocks.

Gainers/Losers

Industry Market Map

Earnings Review-Q2 FY25-26

Stock News

Bajaj Finance raises Rs 1,588 crore by selling nearly 2% stake in Bajaj Housing Finance

Asian Paints shares jump 3%, hit new 52-week high after UBS upgrades stock to 'Neutral': Check latest target price

SPARC shares soar 20% after US district court passes favourable judgement for Sezaby PRV

IPO-bound Meesho's increasing reliance on in-house low logistics arm could hurt Delhivery: Jefferies

Wockhardt shares jump 6%, extend gain to 27% in two days after US FDA accepts new drug application for Zaynich

Photographic Products Industry Stocks
Check latest stock performance, list of stocks, earnings review & more details about the Photographic Products industry stocks.